DGAP-News

Evonik Industries AG: Evonik specifies outlook for 2016 following a good second quarter

DGAP-News: Evonik Industries AG / Key word(s): Half Year Results
Evonik Industries AG: Evonik specifies outlook for 2016 following a good
second quarter

05.08.2016 / 07:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Embargoed until 7 a.m. on August 5, 2016



Key Financial Data:
First half/second quarter 2016


Evonik specifies outlook for 2016 following a good second quarter

- Evonik increases volumes in the first six months

- Adjusted EBITDA margin continues at very good level of 18.1 percent in
the first six months

- Adjusted net income above EUR500 million

- Outlook for the full year specified: adjusted EBITDA in the upper half
of the anticipated range of EUR2.0 billion to EUR2.2 billion

Essen. Demand for Evonik's products rose worldwide in the first half of
this year. "We were able to increase volumes in persistently challenging
business conditions," said Klaus Engel, Chairman of the Executive Board of
Evonik Industries. "We are now confident that over the full year we will
deliver adjusted EBITDA in the upper half of the anticipated range of
EUR2.0 to EUR2.2 billion."

Evonik registered considerable volume growth in the first six months of
2016, mainly as a result of growth in the second quarter. Despite the
higher volumes, Group sales declined to EUR6,363 million, a drop of 8
percent compared with the first half of 2015, principally because lower raw
material costs were passed on to customers. Adjusted EBITDA was also below
the exceptionally strong prior-period figure at EUR1,150 million. Evonik
once again posted a very good adjusted EBITDA margin of 18.1 percent in the
first half of 2016.

Adjusted EBIT fell 18 percent to EUR795 million in the first six months.
Adjusted net income declined 20 percent to EUR501 million. Net income was
EUR405 million, down 40 percent from the high prior-year level, which
contained the proceeds from the divestment of the stake in Vivawest.

Capital expenditures for property, plant and equipment were EUR371 million
in the first six months of 2016, down 2 percent year-on-year. Despite the
lower operating result, Evonik's free cash flow of EUR208 million was
higher than in the first half of 2015 (EUR166 million). This was due, among
others, to a considerable reduction in net working capital.

Segment performance
In the Nutrition & Care segment, lower selling prices accompanied by almost
unchanged volumes resulted in a drop in both sales and earnings. In the
Resource Efficiency segment higher volumes increased sales and earnings.